Retia Medical Receives FDA 510(k) Clearance for Argos Infinity™, Expanding Cardiovascular Intelligence Across High-Risk Surgical and Critical Care Environments

WHITE PLAINS, N.Y., Feb. 17, 2026 /PRNewswire/ -- Retia Medical today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Argos Infinity™, the company's cardiovascular intelligence software platform designed for high-risk surgical and critical care environments across health systems.

Argos Infinity builds on Retia’s clinically validated Multi-Beat Analysis® (MBA®) algorithm and analyzes real-time physiologic data streams from existing monitoring and tele-ICU systems. By transforming routine signals into actionable cardiovascular insight, Argos Infinity supports earlier recognition of hemodynamic instability in operating rooms and intensive care units.

High-risk patients often begin to deteriorate before changes appear in standard vital signs. In cardiac surgery patients, nearly 70% of low cardiac index time occurs while blood pressure remains normal. Delayed recognition can drive ICU escalation and organ injury, including acute kidney injury (AKI).

Sign up for Blog Updates